Results 51 to 60 of about 455 (134)

Methodology for the Development of the Allergic Rhinitis and Its Impact on Asthma (ARIA)‐EAACI 2024–2025 Guidelines: From Evidence‐to‐Decision Frameworks to Digitalised Shared Decision‐Making Algorithms

open access: yesAllergy, Volume 81, Issue 2, Page 427-453, February 2026.
The Allergic Rhinitis and its Impact on Asthma (ARIA) group is working on the 2024–2025 update of its guidelines for the management of allergic rhinitis (ARIA 2024–2025). The ARIA 2024–2025‐EAACI guidelines will follow GRADE methodology and will incorporate evidence from different sources, including systematic reviews and meta‐analyses, mHealth data ...
Jean Bousquet   +230 more
wiley   +1 more source

Secukinumab in the Treatment of Moderate‐to‐Severe Hidradenitis Suppurativa: Pooled Pharmacokinetics and Safety Results From the SUNSHINE and SUNRISE Phase 3 Studies

open access: yesInternational Journal of Dermatology, Volume 65, Issue 2, Page 289-298, February 2026.
ABSTRACT Background Secukinumab, a fully human, monoclonal antibody targeting interleukin‐17A, is approved for moderate‐to‐severe HS in adults. This study evaluated pharmacokinetics (PK), high‐sensitivity C‐reactive protein (hsCRP) changes, and safety of secukinumab over 52 weeks in SUNSHINE and SUNRISE Phase 3 trials.
Afsaneh Alavi   +13 more
wiley   +1 more source

Safety and efficiency of peanut oral immunotherapy in preschool children with slow up-dosing and low maintenance dosing: a randomised controlled trialResearch in context

open access: yesThe Lancet Regional Health. Europe
Summary: Background: Oral immunotherapy (OIT) is an emerging treatment for peanut allergy. A variety of protocols have been investigated, and accumulating evidence suggests that younger children may benefit from greater immune plasticity. The aim of the
Susanna Klevebro   +10 more
doaj   +1 more source

Perceived Acquired Resistance to Omalizumab in Obese Patients With Chronic Spontaneous Urticaria

open access: yes
Clinical &Experimental Allergy, Volume 56, Issue 6, Page 671-673, June 2026.
Francisco Martins   +3 more
wiley   +1 more source

Serum Haptoglobin as a Predictor of Treatment Response in Patients With Chronic Spontaneous Urticaria

open access: yesClinical and Translational Allergy, Volume 16, Issue 1, January 2026.
ABSTRACT Background Chronic spontaneous urticaria (CSU) is a mast cell‐driven disease associated with systemic inflammation and altered immune responses. Haptoglobin (HP), an acute‐phase glycoprotein, exhibits antioxidative and immunomodulatory properties, while zonulin, the precursor of HP‐2, regulates epithelial barrier integrity. We investigated the
Kun‐Woo Park   +4 more
wiley   +1 more source

Long‐Term Real‐World Effectiveness of Rupatadine in Chronic Urticaria: A Retrospective Observational Study

open access: yesJEADV Clinical Practice, Volume 4, Issue 5, Page 1025-1032, December 2025.
This retrospective observational study analyzed a cohort of chronic urticaria (CU) patients to provide insight into the clinical practice of CU with second‐generation antihistamines (SgAHs) and to evaluate the long‐term real‐world effectiveness of rupatadine in CU. Patients with chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU)
A. M. Giménez‐Arnau   +5 more
wiley   +1 more source

Effectiveness, Safety, and Tolerability of Bilastine Up-Dosing in Chronic Spontaneous Urticaria Uncontrolled with Licensed Doses of Other Second-Generation Antihistamines—An Institution-Based, Open-Label, Single-Group Longitudinal Trial

open access: yesIndian Dermatology Online Journal
Background: Bilastine 20 mg daily is a second-generation antihistamine (sgAH) approved for chronic spontaneous urticaria (CSU). Up-dosing to 40 or 80 mg daily is recommended in uncontrolled patients.
Sankha S. Chakraborty   +3 more
doaj   +1 more source

Treatment of recalcitrant chronic urticaria with nonsedating antihistamines: is there evidence for updosing?

open access: yesJournal of investigational allergology & clinical immunology, 2013
Nonsedating antihistamines are the first-choice treatment for all forms of urticaria. In patients with recalcitrant urticaria who do not respond to conventional doses of antihistamines, current guidelines recommend increasing doses by up to 4 times in order to obtain better control of the disease.
M, Sánchez-Borges   +2 more
openaire   +1 more source

Omalizumab Updosing in Chronic Spontaneous Urticaria

open access: yes
Chronic spontaneous urticaria (CSU) is defined as the spontaneous development of itchy hives and/or angioedema due to known or unknown causes that last for at least 6 weeks. At any given time, CSU is believed to affect 0.5-1% of the global population.
Metz, Martin||   +3 more
openaire   +1 more source

Chronic urticaria in children can be controlled effectively with updosing second-generation antihistamines [PDF]

open access: yesJournal of the American Academy of Dermatology, 2020
Sofianne, Gabrielli   +7 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy